| 1 | 1 | | FIRSTREGULARSESSION |
|---|
| 2 | 2 | | HOUSEBILLNO.1118 |
|---|
| 3 | 3 | | 103RDGENERALASSEMBLY |
|---|
| 4 | 4 | | INTRODUCEDBYREPRESENTATIVEBROWN(16). |
|---|
| 5 | 5 | | 2277H.01I JOSEPHENGLER,ChiefClerk |
|---|
| 6 | 6 | | ANACT |
|---|
| 7 | 7 | | Torepealsection208.176,RSMo,andtoenactinlieuthereoftwonewsectionsrelatingto |
|---|
| 8 | 8 | | abuse-deterrentopioidanalgesicdrugproducts. |
|---|
| 9 | 9 | | BeitenactedbytheGeneralAssemblyofthestateofMissouri,asfollows: |
|---|
| 10 | 10 | | SectionA.Section208.176,RSMo,isrepealedandtwonewsectionsenactedinlieu |
|---|
| 11 | 11 | | 2thereof,tobeknownassections208.176and376.1239,toreadasfollows: |
|---|
| 12 | 12 | | 208.176.1.ByDecember1,1992,theMOHealthNetdivisionshall,eitherdirectlyor |
|---|
| 13 | 13 | | 2throughcontractwithaprivateorganization,provideforaprospectivereviewofdrugtherapy. |
|---|
| 14 | 14 | | 3Thereviewshallincludescreeningforpotentialdrugtherapyproblems,duplication, |
|---|
| 15 | 15 | | 4contraindications,interactions,incorrectdrugdosage,drugallergy,durationoftherapyand |
|---|
| 16 | 16 | | 5clinicalabuseormisuse. |
|---|
| 17 | 17 | | 6 2.Anypriorauthorizationrequirementsforopioidanalgesicandanyservice |
|---|
| 18 | 18 | | 7denialsmadepursuanttheretoshallnotrequireuseofopioidanalgesicdrugproducts |
|---|
| 19 | 19 | | 8withoutabuse-deterrentpropertiesbeforeauthorizingtheuseofabuse-deterrentopioid |
|---|
| 20 | 20 | | 9analgesicdrugproducts. |
|---|
| 21 | 21 | | 376.1239.1.Asusedinthissection,thefollowingtermsmean: |
|---|
| 22 | 22 | | 2 (1)"Abuse-deterrentopioidanalgesicdrugproduct",abrandorgenericopioid |
|---|
| 23 | 23 | | 3analgesicdrugproductapprovedbythefederalFoodandDrugAdministrationwith |
|---|
| 24 | 24 | | 4abuse-deterrencelabelingclaimsindicatingitsabuse-deterrentpropertiesareexpected |
|---|
| 25 | 25 | | 5todeterorreduceitsabuse; |
|---|
| 26 | 26 | | 6 (2)"Cost-sharing",anycoveragelimit,co-payment,coinsurance,deductible,or |
|---|
| 27 | 27 | | 7otherout-of-pocketpatientexpenserequirements; |
|---|
| 28 | 28 | | EXPLANATION—Matterenclosedinbold-facedbrackets[thus] intheabovebillisnotenactedandis |
|---|
| 29 | 29 | | intendedtobeomittedfromthelaw.Matterinbold-facetypeintheabovebillisproposedlanguage. 8 (3)"Opioidanalgesicdrugproduct",adrugintheopioidanalgesicdrugclass |
|---|
| 30 | 30 | | 9prescribedtotreatmoderatetoseverepainorotherconditions,whetherinimmediate |
|---|
| 31 | 31 | | 10releaseorextendedlong-actingreleaseformandwhetherornotcombinedwithother |
|---|
| 32 | 32 | | 11drugsubstancestoformasingledrugproductorotherdosageform. |
|---|
| 33 | 33 | | 12 2.Aninsurancecarrierorhealthplanshallprovidecoverageonitsformulary, |
|---|
| 34 | 34 | | 13druglist,orotherlistsofsimilarconstructforatleastoneabuse-deterrentopioid |
|---|
| 35 | 35 | | 14analgesicdrugproductperopioidanalgesicsactiveingredient. |
|---|
| 36 | 36 | | 15 3.(1)Cost-sharingforbrandnameabuse-deterrentopioidanalgesicdrug |
|---|
| 37 | 37 | | 16productscoveredpursuanttothissectionshallnotexceedthelowestcost-sharinglevel |
|---|
| 38 | 38 | | 17appliedtobrandnamenon-abusedeterrentopioiddrugscoveredundertheapplicable |
|---|
| 39 | 39 | | 18healthplanorpolicy. |
|---|
| 40 | 40 | | 19 (2)Cost-sharingforgenericabuse-deterrentopioidanalgesicdrugproducts |
|---|
| 41 | 41 | | 20coveredpursuanttothissectionshallnotexceedthelowestcost-sharinglevelappliedto |
|---|
| 42 | 42 | | 21genericnon-abusedeterrentopioiddrugscoveredundertheapplicablehealthplanor |
|---|
| 43 | 43 | | 22policy. |
|---|
| 44 | 44 | | 23 (3)Anincreaseinpatientcost-sharingordisincentivesforprescribersor |
|---|
| 45 | 45 | | 24dispensersshallnotbeallowedtoachievecompliancewiththissection. |
|---|
| 46 | 46 | | 25 4.Anyprior-authorizationrequirementsorotherutilizationreviewmeasuresfor |
|---|
| 47 | 47 | | 26opioidanalgesics,andanyservicedenialsmadepursuantthereto,shallnotrequireuse |
|---|
| 48 | 48 | | 27ofopioidanalgesicdrugproductswithoutabuse-deterrentpropertiesinordertoaccess |
|---|
| 49 | 49 | | 28abuse-deterrentopioidanalgesicdrugproducts. |
|---|
| 50 | 50 | | âś” |
|---|
| 51 | 51 | | HB1118 2 |
|---|